Valbenazine Tosylate

CHEMBL3707248 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
763.0 g/mol
LogP
Phase
4

Valbenazine tosylate is the tosylate salt form of valbenazine, a selective VMAT2 inhibitor approved for tardive dyskinesia treatment. The tosylate salt form is the pharmaceutical formulation used in the marketed product (Ingrezza), providing appropriate solubility and stability for oral capsule administration. It works by reducing presynaptic dopamine release in the basal ganglia, attenuating the abnormal involuntary movements of tardive dyskinesia.

น้ำหนักโมเลกุล

763.0000 g/mol

TPSA

200.00 Ų

กลไกการออกฤทธิ์

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1

InChI

InChI=1S/C24H38N2O4.2C7H8O3S/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4;2*1-6-2-4-7(5-3-6)11(8,9)10/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3;2*2-5H,1H3,(H,8,9,10)/t17-,19-,20-,23+;;/m1../s1

Molecular Formula

C38H54N2O10S2

HBD / HBA

3 / 12

พันธะที่หมุนได้

10

อะตอมหนัก

52

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Valbenazine tosylate is the tosylate salt form of valbenazine, a selective VMAT2 inhibitor approved for tardive dyskinesia treatment. The tosylate salt form is the pharmaceutical formulation used in the marketed product (Ingrezza), providing appropriate solubility and stability for oral capsule administration. It works by reducing presynaptic dopamine release in the basal ganglia, attenuating the abnormal involuntary movements of tardive dyskinesia.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Valbenazine Tosylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707248. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 92042922. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.